The tweet was deleted by the author.
But we saved everything 🙂.
Quantum-Si will present its innovative single-molecule protein sequencing technology at the European Society of Human Genetics (ESHG) conference.
The company aims to demonstrate how this approach can detect subtle amino acid changes that result in protein variants, playing a vital role in conditions such as hemoglobinopathies. According to Quantum-Si, their technology holds potential for advancing clinical research and improving patient outcomes in the study of hemoglobin disorders. Additional insights will be provided by the company’s Senior Field Application team at the event.
Quantum-Si recently collaborated with the University of Virginia to unveil advanced data on post-translational modification detection at the ASMS conference. The company has also participated in investor-focused events, with CEO Jeff Hawkins joining a discussion at the H.C.Wainwright BioConnect Investor Conference. These appearances mark ongoing engagement with both scientific and investor communities.